Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click for why LLY growth remains strong.

Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid growth prospects.

Eli Lilly & Co.’s shares dropped in morning trading after CVS Health Corp. announced a plan to drop its blockbuster weight-loss drug Zepbound, making rival Wegovy more widely available.The drugmaker also cut its full-year earnings outlook,

Shares of Eli Lilly ( LLY -5.50%) are sliding on Thursday. The stock lost 8.3% as of 12:21 p.m. ET. The leg down comes as the S&P 500 ( ^GSPC -0.77%) gained 1% and the Nasdaq Composite ( ^IXIC -0.87%) gained 1.9%.

Eli Lilly’s LLY first-quarter revenue grew 45%, as combined sales for Mounjaro (diabetes) and Zepbound (obesity ... future competitors means non-GAAP performance margin (similar to operating ...